Share chart PepGen Inc.
Extended chart
Simple chart
About PepGen Inc.
PepGen Inc., биотехнологическая компания клинической стадии, занимается разработкой олигонуклеотидных терапевтических средств для лечения тяжелых нервно-мышечных и неврологических заболеваний. Ведущим продуктом компании-кандидата является PGN-EDO51, пептид EDO, проходящий фазу I клинических испытаний для лечения пациентов с мышечной дистрофией Дюшенна (МДД). Он также разрабатывает PGN-EDODM1, конъюгированный с пептидом EDO PMO для лечения миотонической дистрофии 1 типа, а также терапевтические кандидаты EDO, такие как PGN-EDO53, PGN-EDO45 и PGN-EDO44 для лечения МДД. more details| IPO date | 2022-05-06 |
|---|---|
| ISIN | US7133171055 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://www.pepgen.com |
| Цена ао | 1.57 |
| Change price per day: | -8.93% (1.68) |
|---|---|
| Change price per week: | +15.04% (1.33) |
| Change price per month: | -2.55% (1.57) |
| Change price per 3 month: | -21.13% (1.94) |
| Change price per half year: | -79.95% (7.63) |
| Change price per year: | -87.18% (11.93) |
| Change price per year to date: | -59.63% (3.79) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| RA Capital Management, L.P. | 8131952 | 25.13 |
| Viking Global Investors, L.P. | 1482434 | 4.58 |
| Adage Capital Partners GP L.L.C. | 1100000 | 3.4 |
| Janus Henderson Group PLC | 988204 | 3.05 |
| FMR, LLC | 738022 | 2.28 |
| Blackrock Inc. | 723538 | 2.24 |
| Laurion Capital Management, LP | 664516 | 2.05 |
| Vanguard Group Inc | 506179 | 1.56 |
| Suvretta Capital Management, LLC | 486611 | 1.5 |
| Samsara BioCapital, LLC | 436813 | 1.35 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Dr. James G. McArthur Ph.D. | President, CEO, Treasurer, Secretary & Director | 834.98k | 1962 (63 years) |
| Dr. Michelle L. Mellion M.D. | Chief Medical Officer | N/A | 1976 (49 years) |
| Mr. Niels Svenstrup Ph.D. | Senior Vice President of Chemistry, Manufacturing & Control | 455.15k | 1970 (55 years) |
| Mr. Noel P. Donnelly M.B.A. | Chief Financial Officer | 650.17k | 1970 (55 years) |
| Dr. Michael Gait Ph.D. | Founder & Scientific Advisory Board Member | N/A | |
| Ms. Emiko Bryant | Chief of Staff | N/A | |
| Mr. David E. Borah C.F.A. | Senior VP of IR & Corporate Communications | ||
| Ms. Mary Beth DeLena J.D. | General Counsel & Secretary | 1968 (57 years) | |
| Dr. Hayley Parker Ph.D. | Senior Vice President of Global Regulatory Affairs | ||
| Dr. Afsaneh Mohebbi Ph.D. | Senior VP of Portfolio and Program Management |
Address: United States, Cambridge. MA, 245 Main Street - open in Google maps, open in Yandex maps
Website: https://www.pepgen.com
Website: https://www.pepgen.com
